291 related articles for article (PubMed ID: 25716771)
1. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula.
Sjögren V; Grzymala-Lubanski B; Renlund H; Friberg L; Lip GY; Svensson PJ; Själander A
Thromb Haemost; 2015 Jun; 113(6):1370-7. PubMed ID: 25716771
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
[TBL] [Abstract][Full Text] [Related]
3. Predictors for INR-control in a well-managed warfarin treatment setting.
Björck F; Kadhim H; Själander A
J Thromb Thrombolysis; 2019 Feb; 47(2):227-232. PubMed ID: 30411185
[TBL] [Abstract][Full Text] [Related]
4. Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.
Sandén P; Renlund H; Svensson PJ; Själander A
Thromb Haemost; 2017 Jan; 117(1):27-32. PubMed ID: 27652593
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.
Wieloch M; Själander A; Frykman V; Rosenqvist M; Eriksson N; Svensson PJ
Eur Heart J; 2011 Sep; 32(18):2282-9. PubMed ID: 21616951
[TBL] [Abstract][Full Text] [Related]
8. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation.
Lind M; Fahlén M; Kosiborod M; Eliasson B; Odén A
Thromb Res; 2012 Jan; 129(1):32-5. PubMed ID: 21851969
[TBL] [Abstract][Full Text] [Related]
9. Impact of prophylactic oseltamivir on INR in patients on stable warfarin therapy.
Smith KR; Bryan WE; Townsend ML; Randolph AE; Vanderman AJ; Woodard CL; Brown JN
J Thromb Thrombolysis; 2020 Aug; 50(2):452-456. PubMed ID: 31898274
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
[TBL] [Abstract][Full Text] [Related]
11. Differences in the risk of stroke, bleeding events, and mortality between female and male patients with atrial fibrillation during warfarin therapy.
Penttilä T; Lehto M; Niiranen J; Mehtälä J; Khanfir H; Lassila R; Raatikainen P
Eur Heart J Cardiovasc Pharmacother; 2019 Jan; 5(1):29-36. PubMed ID: 30052822
[TBL] [Abstract][Full Text] [Related]
12. D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.
Yamamoto R; Nakae Y; Tanaka F; Johkura K
J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1781-1785. PubMed ID: 27103270
[TBL] [Abstract][Full Text] [Related]
13. Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
Pokorney SD; Holmes DN; Thomas L; Fonarow GC; Kowey PR; Reiffel JA; Singer DE; Freeman JV; Gersh BJ; Mahaffey KW; Hylek EM; Naccarelli GV; Ezekowitz MD; Piccini JP; Peterson ED;
JAMA Cardiol; 2019 Aug; 4(8):756-764. PubMed ID: 31268487
[TBL] [Abstract][Full Text] [Related]
14. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
[TBL] [Abstract][Full Text] [Related]
15. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Piccini JP; Hellkamp AS; Lokhnygina Y; Patel MR; Harrell FE; Singer DE; Becker RC; Breithardt G; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2014 Apr; 3(2):e000521. PubMed ID: 24755148
[TBL] [Abstract][Full Text] [Related]
16. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
Hirano T; Kaneko H; Mishina S; Wang F; Morita S
J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
[TBL] [Abstract][Full Text] [Related]
17. Warfarin persistence among atrial fibrillation patients - why is treatment ended?
Björck F; Ek A; Johansson L; Själander A
Cardiovasc Ther; 2016 Dec; 34(6):468-474. PubMed ID: 27565120
[TBL] [Abstract][Full Text] [Related]
18. Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA
Denas G; Zoppellaro G; Padayattil Jose S; Antonucci E; Marongiu F; Poli D; Testa S; Tripodi A; Palareti G; Pengo V
Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29078033
[TBL] [Abstract][Full Text] [Related]
19. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation.
Williams BA; Evans MA; Honushefsky AM; Berger PB
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29025746
[TBL] [Abstract][Full Text] [Related]
20. Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice.
An J; Niu F; Lang DT; Jazdzewski KP; Le PT; Rashid N; Meissner B; Mendes R; Dills DG; Aranda G; Bruno A
J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26187996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
